An observational study in Latent Tuberculosis Infection, HIV Infections and Tuberculosis, sponsored by Ministry of Science and Technology, India. Status unknown at 1 site in India. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-09-15.
Sponsored by Ministry of Science and Technology, India · Observational
HIV induced altered representation and function of regulatory T cell subsets (NKT and Treg cells) impair the protective T cell response against M.tuberculosis and disrupts LTBI, thus facilitates faster progression and development of severe forms of clinical TB in HIV-TB co-infection.
During the natural course of HIV disease, emergence of opportunistic infection not only imposes morbidity on HIV-TB co-infected patients, but also facilitates viral replication causing faster disease progression. Tuberculosis, being the commonest among the opportunistic infections among HIV infected persons deserves special attention. Moreover, disruption of latency of TB infection (LTBI) with development of more severe clinical forms at relatively early stage of HIV disease when CD4 count still remains above 300/ul, makes TB a unique opportunistic infection and negatively influence the outcome of dual infection.This is suggestive of impairment of some critical immune function involving relatively less frequent fine T cell subsets with functional hierarchy over bulk T cells, so as to weaken the immune containment of LTBI resulting in reactivation of M. tuberculosis and manifestation of severe forms of TB.HIV has recently been reported to preferentially infect, destroy and incapacitate two key immune-regulatory T cell subsets, namely NKT and Treg cells.Therefore, studying them along the course of HIV disease and impact of their changes on the function of effector T cells directed against M.tuberculosis is important.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's planned enrollment of 180 is below the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Ministry of Science and Technology, India is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
HIV+ve+LTBI HIV+ve+clinical TB HIV-ve+clinical TB Normal control
HIV infected +LTBI group:
HIV infected + Clinical TB group:
In EPTB group, diagnosis of TB will be:
HIV negative Clinical TB group:
In EPTB group, diagnosis of TB will be:
Normal controls:
Person should not have past history of TB
Exclusion Criteria:
HIV infected +LTBI group:
HIV infected + Clinical TB group:
HIV negative Clinical TB group:
Normal controls:
HIV+ve+LTBI (n=100)
HIV+ve+clinical TB (n=50)
HIV-ve+clinical TB (n=15)
Normal control (n=15)
Precise component(s) of T cell response against M.tuberculosis compromised by HIV infection which leads to the development of severe forms of clinical tuberculosis.
Time frame: 5 months
Elucidation of critical events of the cellular and molecular interactions that would be useful for developing newer therapeutic strategies and vaccination.
Time frame: 5 months
This study is status unknown, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ministry of Science and Technology, India